N
Nagi Bioscience
Nagi Bioscience aims to revolutionize the way toxic and/or beneficial effects of substances are tested
About Nagi Bioscience
Nagi Bioscience is a Swiss startup operating in the biotechnology sector, specializing in laboratory technologies for next-generation alternative testing. The company's primary offering is the SydLab™ ONE, a technology that automates screenings on micro-organisms, allowing researchers to focus on their results rather than the testing process. This automation also provides unprecedented levels of standardization and reproducibility, which are crucial in scientific research.
Nagi Bioscience serves a diverse range of clients, including agrochemical companies and aging biotech companies. These clients utilize Nagi's technologies to identify adverse toxicology as early as possible in their R&D pipelines, reducing the cost of late-stage failures. The company's technologies also offer methodologies to assess lifespan and healthspan measures in a high-throughput manner, particularly in the C. elegans field, a model organism widely used in biological research.
The business model of Nagi Bioscience is centered around providing tailored services for exceptional research. By pioneering the Organism-on-Chip technologies, the company bridges the gap between cells and vertebrates seamlessly, making micro-organisms testing easy and efficient. The company generates revenue by selling their innovative technologies and providing services to their clients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Saint-Sulpice, Switzerland
- Employees
- 58
- Open positions
- None listed
- Dealroom signal
- 83.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Drug Development, Spinout, Tech for Biotech and Pharma, AI Drug Discovery, Techbio, Hard Tech, Techbio Drug Discovery
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Sep 2025 | $0 | — | Innosuisse | ↗ |
| SUPPORT PROGRAM✓Other financing | Jan 2025 | $0 | — | Swissnex | — |
Growth signals
Latest recorded traffic for Nagi Bioscience is 600 monthly website visits, down 72.7% over the last three months. Nagi Bioscience's team grew 5.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Venture Kick
Verve Ventures
ZKB - Zürcher Kantonalbank
Nest Collective Foundation
European Innovation Council
Innosuisse
Series A3 investors entered at this stage
Swisscanto Invest
imec.xpand
Excellis
Other known investors6 additional known investors
Swissnex
EPFL Swiss Federal Polytechnic School of Lausanne
Startup Campus
EPFL Innovation Park
MassChallenge
VentureLab
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nagi Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nagi Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.